Cite
HARVARD Citation
Shibaki, R. et al. (2021). A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study). Therapeutic advances in medical oncology. p. . [Online].